Cencora Bets $1.1 Billion on Retina Care — and the Math Makes Sense

Cencora (NYSE: COR) is making its biggest move yet in specialty eye care, agreeing to acquire the retina business of EyeSouth Partners for $1.1 billion, a deal that could more than double its footprint in one of healthcare’s most underserved subspecialties.

Under the agreement, EyeSouth’s affiliated retina physicians will join Cencora’s Retina Consultants of America (RCA), the company’s physician-centered management services organization. The transaction is pending regulatory approval and customary closing conditions.

Why It Matters

Retina care is a high-acuity, high-demand specialty, and Cencora has been quietly building scale in it. Currently holding an estimated 1–2% share of the retina market with roughly 300 physicians, the EyeSouth acquisition would more than double that physician count to over 700, pushing market share to approximately 3% or higher.

That’s not incremental growth. That’s category repositioning.

EyeSouth’s affiliated physicians will also gain access to RCA’s clinical trial and research offerings— strengthening Cencora’s value proposition to both physicians and patients, and creating a platform that becomes harder to replicate at scale.

The Investor Case

Cencora expects the deal to be slightly accretive to adjusted diluted EPS within the first 12 months following close, net of financing costs. For a $1.1 billion transaction, that’s a meaningful signal on deal discipline.

The company reaffirmed its fiscal 2026 guidance, which does not currently contemplate the transaction closing this fiscal year— meaning any contribution would represent upside to current estimates. BofA Securities analyst Allen Lutz noted the acquisition is consistent with Cencora’s broader capital deployment strategy.

What to Watch

Regulatory clearance is the primary near-term gating factor. Additionally, Cencora’s CFO James Cleary is set to retire after more than seven years in the role, a leadership transition investors will want to monitor as the company integrates a deal of this magnitude.

Bottom Line

This isn’t a diversification play — it’s a focused bet on specialty care consolidation. Cencora is building a scaled retina platform at a moment when physician networks, clinical infrastructure, and distribution expertise are converging. For investors, the combination of EPS accretion, reaffirmed guidance, and a defensible market position makes this a deal worth tracking closely.